

PATENT

Docket No.: 1290-7281

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Bouchard, et al. Group Art Unit: 1203  
Serial No. : 08/162,984 Examiner: B. Trinh  
Filed : December 8, 1993  
For : NEW TAXOIDS, THEIR PREPARATION AND  
PHARMACEUTICAL COMPOSITION CONTAINING THEM

DECLARATION OF FRANCOIS LAVELLE

Honorable Commissioner of Patents & Trademarks  
Washington, D.C. 20231

Sir:

I, FRANCOIS LAVELLE, make the following declaration:


1. I am employed as the Director of the Department of Biologie, Service de Cancérologie by RHÔNE-POULENC RORER RECHERCHE-DÉVELOPPEMENT, the wholly owned subsidiary of RHÔNE-POULENC RORER S.A., the assignee of the above-identified application (the "'984 Application").
2. I received a Doctorat ès Sciences at the Université de Paris. I have been employed in the position of Director of the Department of Biologie, Service de Cancérologie for 17 years. Included in my responsibilities is the supervision of biological assays of compounds for anti-tumor activity and in particular the assay of compounds in the taxoid family for properties of tumor cell growth inhibition and tumor cell death. I am a co-author on numerous publications including those listed in attached Appendix I.

Based upon my professional and educational background and experience, I am familiar with the subject relating to TAXOL®, TAXOTERE® anti-tumor compounds, their derivatives and their pharmacological profiles including their anti-tumor properties. In this declaration, I will present and explain the results of studies comparing the anti-tumor properties of the cyclopropyl taxoid compound referred to herein as Compound I with its closest structural analogues disclosed in the '984 application and U.S. Patent No. 5,254,580 (10/19/93) to Chen et al. assigned to Bristol-Myers Squibb (the "'580 patent").


3. I organized and directly supervised the pharmacological study of taxoid compounds disclosed in the "'580 patent". Among the TAXOL and TAXOTERE derivatives disclosed therein is the compound I will refer to as Compound I, N-debenzoyl-N-t-butoxycarbonyl-7-deoxy-8-desmethyl-7,8-cyclopropataxol which is referenced in Example 23 and claim 7 of the '580 patent.

4. Compound I is described and supported in the '984 application at page 4, lines 21-24, and claimed by virtue of claim 53 and claim 102.

5. For purposes of more easily comprehending the comparative data which follows, the structural formulae of TAXOL and TAXOTERE anti-tumor compounds are provided hereinbelow:



TAXOL




TAXOTERE

) 8 )


There are two structural differences between the two above compounds: at the 10-position TAXOL has an acetyl group (OAc) whereas TAXOTERE has an hydroxy group (OH), and on the nitrogen at the 3' position of the side chain, TAXOL has a phenylcarbonyl group (C<sub>6</sub>H<sub>5</sub>CO-) whereas TAXOTERE has a tert-butoxy-carbonyl group (t-BuOCO-).

The derivatives disclosed in the '580 patent and the '984 application are derivatives of TAXOL and TAXOTERE in which the 7,8-position is modified to provide a cyclopropyl derivative. Compound I, for instance, has the following structural formula:




COMPOUND I

6. In my position at RHÔNE-POULENC RORER, I have supervised biological studies which compare the anti-tumor properties of Compound I with its two most closely structurally related compounds (compounds II and III), both of which are disclosed in the '580 patent and whose formulae are provided hereinbelow:



II

122



III

Compound II, having the TAXOTERE nucleus, differs from Compound I in that it has an hydroxy group instead of the acetoxy group at position 10.

Compound III, having the TAXOL nucleus, differs from Compound I in that instead of the t-butoxy group on the side-chain, has a phenyl group.

7. The biological studies which I supervised compared the in vitro and in vivo anti-tumor properties of Compounds I, II and III. In the in vitro study, the anti-tumor properties of compounds I, II and III were compared against two different tumor cell lines characterized by either the presence or the absence of the multi-drug resistance gene.

#### Description of the In Vitro Test

The *in vitro* activity is evaluated in the P388 murine leukemia cell line and the P388 murine leukemia cell line resistant to doxorubicine and containing the multi-drug resistance gene (P388/DOX).

3x10<sup>5</sup> cells/ml were ~~grown~~ <sup>grown</sup> for 96 hours in the presence of various drug concentrations. Cells were then incubated for 16 hours with 0.02% natural red, washed and lyzed with 1% SDS (sodium dodecyl sulphate).

The incorporation of the dye reflecting the cellular growth was assayed by optical density measurement at 540 and 346 nm.

The concentration of the drugs resulting in 50% growth inhibition (IC<sub>50</sub>) was then determined: the lower the IC<sub>50</sub> value the higher the ~~selectivity~~ <sup>potency</sup> of the compound.

183 potency FL 12.27.94

FL 12.27.94

FL 12/27/94

15  
FL 12/27/94

expressing

The lower the ratio  $(IC_{50}\text{-P388/DOX}) / (IC_{50}\text{-P388})$ , the "Resistance Factor R", the higher the activity of the compound as an effective tumor cell growth inhibitor of multi-drug resistant cell lines.

The results of the comparative in vitro study are presented in the following table A.

Compound	TABLE A $IC_{50}$ ( $\mu\text{g/ml}$ )		Resistance Factor R
	P 388	P 388/DOX	
I	0.03	0.25	8
II	0.03	0.45	15
III	0.085	1.80	21

#### Description of the In Vivo Test

In the in vivo study, antitumor activity of compounds I, II and III were evaluated in B16 melanoma bearing mice wherein tumors were implanted as subcutaneous bilateral fragments in B6 D2F1 mice.

#### Description of the methodology

The animals necessary to begin a given experiment were pooled and implanted - subcutaneously bilaterally with 30 to 60 mg tumor fragment on day 0 with a 12 gauge trocar. Bilateral implants were used to insure a more uniform burden per mouse and thus reduce the requirement for a greater number of mice per group.

For an early stage tumor treatment, the tumor-bearing animals were again pooled before unselected distribution to the various treatment and control groups.

For an advanced stage treatment, the solid tumors were allowed to grow to the desired size range (animals with tumors not in the desired range were excluded). The mice were then pooled and unselectively distributed to the various treatment and control groups.

Non tumor bearing animals (NTBA) were often matched to tumor-bearing groups and given the same route, dose and schedules. In this way, drug-induced toxicity can be clearly separated from the effects of the tumors.

Chemotherapy was started within 3 to 24 days after tumor implantation. Mice were checked daily and adverse clinical reactions were noted.

Each group of mice was weighed as a whole three to five times weekly until the weight nadir was reached. The groups were weighed once or twice weekly until the end of the experiment.

Tumors were measured with a caliper twice or three times weekly until the tumors reached 2,000 mg or until the animal died (whichever comes first).

Solid tumor weights were estimated from two dimensional tumor measurements

$$\text{Tumor weight (mg)} = \frac{\text{length (mm)} \times \text{width 2 (mm)}^2}{2}$$

The day of death was recorded. Surviving animals were killed and macroscopic examination of the thoracic and abdominal cavities was carried out. In some cases, tissue samples were submitted to histological evaluation.

- End point for assessing antitumor activity

Antitumor activity evaluation was done at the highest non-toxic dosage (HNTD). A dosage producing 20 % weight loss nadir (mean group) or 20 % or more drug deaths, was considered an excessively toxic dosage. Animal body weights included tumor weights.

- Tumor growth inhibition (T/C)

The treatment and control groups were measured when the median of the control group tumors reached approximately 750 to 1,200 mg the median tumor weight of each group was determined.

The T/C value in percent is an indication of antitumor effectiveness:

$$\text{T/C (\%)} = 100 \times \frac{\text{median tumor weight of the treated groups}}{\text{median tumor weight of the control groups}}$$

According to NCI (National Cancer Institute) standards, a T/C < 42 % (score : +) is the minimal level to declare activity. A T/C < 10 % (score : ++) is considered to indicate high antitumor activity and is the level used by NCI to justify further development.

- Tumor growth delay

182

T and C are the median times (in days) required for the treatment group and the control group tumors respectively to reach predetermined size (usually 750 to 1,000 mg). Tumor free survivors are excluded from these calculations and tabulated separately.

This value is the more significant one as it allows the quantification of the tumor cell kill.

- Determination of the tumor doubling time (Td)

Td is estimated from the best fit straight line from a log linear growth plot of the control group tumors in exponential growth (100 to 1,000 mg range).

- Quantification of tumor cell kill

For subcutaneous growing tumors, the total log cell kill is calculated from the following formula:

$$\log \text{ cell kill (gross or total)} = \frac{T - C \text{ value in days}}{3.32 \times Td}$$

where T-C is the tumor growth as described above and Td is the tumor volume doubling time in days.

The log cell kill value can be converted to an arbitrary activity rating with the following table:

Activity	Duration of treatment (5-20 days) log <sub>10</sub> kill gross
Highly active++++	> 2.8
+++	2.0 to 2.8
++	1.3 to 1.9
+	0.7 to 1.2
Inactive-	<0.7

The results of the comparative in vivo study are presented in the following Table B.

TABLE B

Compound	T/C x 100	Score	Log cell kill	Score
I	6	++	2.7	++
II	17	+	1.0	+
III	53	-		-

In the experiments : tumor (B16 melanoma) grafted s.c. on day 0 in mice; i.v. treatment on days 5,7 and 9.

Score (T/C x 100): T/C < 10: ++; T/C between 10 and 42: +; T/C > 42: -

Score (Log cell kill): < 0.7: -; between 1 and 2: +; > 2: ++

CONCLUSION

8. Based upon the results of the biological evaluation shown in the above Tables A and B, it is my professional opinion that Compound I is the superior anti-tumor compound in comparison to the closely related compounds II and III in that compound I is about 2-3 fold more effective than compounds II and III in vitro and by the T/C x 100 and the log cell kill in the in vivo study.

It is my further opinion that the superiority of Compound I over compounds II and III is unexpected in view of their close structural similarities, one having the TAXOTERE nucleus, the other the TAXOL nucleus, and their apparently minor structural differences as described above.

9. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1011 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the '984 Application or any patent issuing thereon.

Date: December 27, 1994

By: Francois Lavelle

Francois Lavelle

188



## APPENDIX I

### PUBLICATIONS

- Luminescence des champignons lumineux  
F. LAVELLE, P. DUROSAY et A.M. MICHELSON  
C.R. Acad. Sci. Paris 275 (1972) - 1227-1230.
  
- Biological protection by superoxide dismutase  
F. LAVELLE, A.M. MICHELSON and L. DIMITRIJEVIC  
Biochem. Biophys. Res. Com. 55 (1973) - 350-357.
  
- Superoxyde dismutase - Fonction et concentration de l'erythrocupréine chez l'humain normal  
F. LAVELLE, K. PUGET et A.M. MICHELSON  
C.R. Acad. Sci. Paris 278 (1974) - 2695-2698.
  
- Purification et étude des deux superoxyde dismutases du champignon *Pleurotus olearius*  
F. LAVELLE et A.M. MICHELSON  
Biochimie 57 (1975) - 375-382.
  
- Superoxide dismutase activities of blood platelets in trisomy 21  
P.M. SINET, F. LAVELLE, A.M. MICHELSON and H. JEROME  
Biochem. Biophys. Res. Com. 67 (1975) - 904-909.
  
- Superoxide dismutases from procaryote and eucaryote bioluminescent organisms  
K. PUGET, F. LAVELLE and A.M. MICHELSON  
in "Superoxide and Superoxide Dismutases"  
Edited by A.M. MICHELSON, J.M. McCORD and I. FRIDOVICH - Academic Press, (1977) - 139-150.
  
- A pulse - radiolysis study of the catalytic mechanism of the iron-containing superoxide dismutase from *Photobacterium leiognathi*  
F. LAVELLE, M.E. McADAM, E. MARTIN FIELDEN, P. ROBERTS, K. PUGET and A.M. MICHELSON  
Biochem. J. 161 (1977) - 3-11.

- A pulse - radiolysis study of the manganese-containing superoxide dismutase from *Bacillus stearothermophilus* : I A kinetic model for the enzyme action  
M.E. McADAM, R.A. FOX, F. LAVELLE and E. MARTIN FIELDEN

Biochem. J. 165 (1977) - 71-79.

- A pulse - radiolysis study of the manganese-containing superoxide dismutase from *Bacillus stearothermophilus* : II. Further studies on the properties of the enzyme  
M.E. McADAM, F. LAVELLE, R.A. FOX and E. MARTIN FIELDEN

Biochem. J. 165 (1977) - 81-87.

- The involvement of the bridging imidazolate in the catalytic mechanism of action of bovine superoxide dismutase  
M.E. McADAM, E. MARTIN FIELDEN, F. LAVELLE, L. CALABRESE, D. COCCO, G. ROTILIO

Biochem. J. 167 (1977) - 271-274.

- Experimental and clinical activity of new anthracycline derivative : detorubicin (14-diethoxyacetoxydaunorubicin)  
R. MARAL, D. HEUSSE, F. LAVELLE, G. CUEILLE, M. MARLARD, C. JACQUILLAT, J. MARAL, M.F. AUCLERC, M. NEIL, G. AUCLERC and J. BERNARD

Recent results in Cancer Research 74 (1980) - 171-183.

- Iron (III)-Adriamycin and iron (III) - Daunorubicin complexes. Physicochemical characteristics, interaction with DNA and antitumor activity.  
H. BERALDO, A. GARNIER-SUILLEROT, L. TOSI, F. LAVELLE

Biochemistry 24 (1985) - 284-289.

- The experimental antitumor activity of 8-carbamoyl-3-(2-chloroethyl)-imidazo[5,1-d]-1, 2, 3, 5-tetrazin-4 (3H)-one (Mitozolomide), a novel broad spectrum agent  
J.A. HICKMAN, M. F.G. STEVENS, N.W. GIBSON, S.P. LANGDON, C. FIZAMES, F. LAVELLE, G. ATASSI and E. LUNT

Cancer Research 45 (1985) - 3008-3013.

- Synthesis and antitumor activity of 3'-C-Methyl-Daunorubicin  
T.T. THANG, J.L. IMBACH, C. FIZAMES, F. LAVELLE, G. PONSINET, A. OLESKER and G. LUKACS

Carbohydrate Research 135 (1985) - 241-247.

- Utilisation de cellules perméabilisées dans l'étude de produits inhibiteurs de la réplication de virus de l'herpes  
I. BAGINSKI, G. COLSON, F. LAVELLE, A. ZERIAL

Pathologie Biologie 33 (1985) - 618-622.

- Structure et Activité des Anthracyclines  
F. LAVELLE

Pathologie Biologie 35 (1987) - 11-19.

- Interface préclinique - Phase I des nouvelles molécules en Cancérologie  
F. LAVELLE

Pharmacologie clinique : Actualités et Perspectives  
Editions de l'INSERM, 156 (1987) - 195-206.

- Protocoles d'étude préclinique des agents antitumoraux  
F. LAVELLE, A. CURAUDEAU

Développement et évaluation du médicament  
Editions de l'INSERM, 157 (1987) - 177-194.

- Synthesis and Experimental Antitumor properties of 6-alkyl (or aryl) thio-5 deazaptéridines  
F. POCHAT, F. LAVELLE, C. FIZAMES and A. ZERIAL

Eur. J. Med. Chem. 22 (1987) - 135-137.

- Antitumor imidazotetrazines - Part 14 - Synthesis and antitumor activity of 6 and 8-substituted imidazo [5,1-d]-1,2,3,5 tetrazinones and 8-substituted pyrazolo [5,1-d]-1,2,3,5-tetrazinones  
E. LUNT, C.G. NEWTON, C. SMITH, G.P. STEVENS, M.F. G. STEVENS, C.G. STRAW, R.J.A. WALSH, P.J. WARREN, C. FIZAMES, F. LAVELLE, S.P. LANGDON and L.M. VICKERS

J. Med. Chem. 30 (1987) - 357-366.

- Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4 (3H) one (CCRG 81 045 ; MB 39 831).  
A novel drug with potential as an alternative to dacarbazine  
M.F. G. STEVENS, J.A. HICKMAN, S.P. LANGDON, D. CHUBB, L. VICKERS, R. STONE, G. BAIG, C. GODDARD, J.A. SLACK, C. NEWTON, E. LUNT, C. FIZAMES and F. LAVELLE.

Cancer Research 47 (1987) - 5846-5852

- La girolline, nouvelle substance antitumorale extraite de l'éponge, *Pseudaxinyssa cantharella* n. sp. (Axinellidae)  
A. AHOND, M. BEDOYA ZURITA, M. COLIN, C. FIZAMES, P. LABOUTE, F. LAVELLE,  
D. LAURENT, C. POUPAT, J. PUSSET, M. PUSSET, O. THOISON et P. POTIER  
  
C. R. Acad. Sci. Paris, t. 307, Série II, 1988, p. 145-148.
  
- Differential sensitivity to pertussis toxin of 3T3 cells transformed with different oncogenes  
I. REY, H. SUAREZ, F. LAVELLE and B. TOCQUE  
  
FEBS Letters, 237 (1988) 203-207.
  
- La stratégie de la recherche des médicaments anticancéreux  
F. LAVELLE  
  
Cancer Communication, 2, 1988, 257-260.
  
- Synthesis and antitumor activity of 1-(dialkylamino)alkylamino-4-methyl-5H-pyrido [4,3-b] benzo [e] (and benzo [g]) indoles. A new class of antineoplastic agents.  
C.H. NGUYEN, J.M. LHOSTE, F. LAVELLE, M.C. BISSERY and E. BISAGNI  
  
J. Med. Chem., 1990, 33, 1519-1528.
  
- The preparation of the 8-acid derivative of mitozolomide, and its utility in the preparation of active anti-tumor agents  
K.R. HORSPOOL, M.F.G. STEVENS, C.G. NEWTON, E. LUNT, R.J.A. WALSH, B.L. PEDGRIFT, G.U. BAIG, F. LAVELLE and C. FIZAMES  
  
J. Med. Chem., 1990, 33, 1393-1399.
  
- Relationships between the structure of taxol analogues and their antimitotic activity  
F. GUERITTE-VOEGELEIN, D. GUENARD, F. LAVELLE, M.T. LE GOFF, L. MANGATAL and P. POTIER  
  
J. Med. Chem., 1991, 34, 992-998.
  
- Antitumor activity and mechanism of action of the marine compound girodazole  
F. LAVELLE, A. ZERIAL, A. CURAUDEAU, B. RABAULT and C. FIZAMES  
  
Investigational New Drugs, 1991, 9, 233-244.

- Heterocyclic quinolones. 17. A new *in vivo* active antineoplastic drug : 6,7-Bis (1-aziridiny)-4-[3-(N,N, dimethylamino) propyl]amino]-5,8-quinazolinedione  
S. GIORGI-RENAULT, J. RENAULT, P. GEBEL-SERVOLLES, M. BARON, C. PAOLETTI, S. CROS, M.C. BISSERY, F. LAVELLE et G. ATASSI

J. Med. Chem., 1991, 34, 38-46.

- Experimental antitumor activity of Taxotere (RP 56976, NSC 628503C), a taxol analog  
M.C. BISSERY, D. GUENARD, F. GUERITTE-VOEGELEIN and F. LAVELLE

Cancer Research, 1991, 51, 4845-4852.

- From the modelization of DNA platination to the conception of new drugs.  
E. SEGAL-BENDIRDJIAN, P. BREHIN, B. LAMBERT, A. LAOUI, J. KOZELKA, J.-M. GARROT, P. MAILLIET, M. BARREAU, F. LAVELLE, A.-M.J. FICHTINGER-SCHEPMAN, A.T. YEUNG, A. JACQUEMIN-SABLON, J.-B. LE PECQ and J.C.-CHOTTARD

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 1991, 37-49.

- Mode of action of the antitumor compound, Girodazole (RP 49532A, NSC 627434)  
G. COLSON, B. RABAULT, F. LAVELLE and A. ZERIAL

Biochem. Pharmacol., 1992, 43, 1717-1723.

- Synthesis and antitumor properties of new 4-methyl-substituted-pyrido[4,3-b]indoles ( $\gamma$ -carbolines).  
C.H. NGUYEN, E. BISAGNI, F. LAVELLE, M.C. BISSERY, and C. HUEL

Anticancer Drug Design, 1992, 7, 219-233.

- Further SAR in the new antitumor 1-amino-substituted  $\gamma$ -carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series.  
C.H. NGUYEN, F. LAVELLE, J.F. RIOU, M.C. BISSERY, C. HUEL and E. BISAGNI

Anticancer Drug Design, 1992, 7, 235-251.

- Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes.  
A. VIRONE, R. MONIER, A. ZERIAL, F. LAVELLE and J. FEUNTEUN

Int. J. Cancer, 1992, 51, 798-804.

- Effects of Taxotere on murine and human tumor cell lines.  
J.F. RIOU, A. NAUDIN and F. LAVELLE

Biochem. Biophys. Res. Com., 1992, 187, 164-170.

- Sequential modifications of topoisomerase I activity in a camptothecin resistant cell line established by progressive adaptation.

I. MADELAINE, S. PROST, A. NAUDIN, G. RIOU, F. LAVELLE and J.F. RIOU

Biochem. Pharmacol., 1993, 45, 339-348.

- Le Taxotère : Des aiguilles d'if à la clinique.

F. LAVELLE, F. GUERITTE-VOEGELEIN et D. GUENARD

Bulletin du Cancer, 1993, 80, 326-338.

- Taxoids.

F. LAVELLE and D.D. VON HOFF

Handbook of Chemotherapy in Clinical Oncology (Scientific Communication International Ltd, 1993, E. CVITKOVIC, J.P. DROZ, J.P. ARMAND, S. KHOURY Edts).

- Taxoids : A new class of antimitotic agents.

F. LAVELLE

Current Opinion in Investigational Drugs, 1993, 2 : 627-635.

- Réalités et perspectives de la recherche pharmaceutique en cancérologie : l'expérience de Rhône-Poulenc Rorer.

F. LAVELLE

Actualités de Chimie Thérapeutique, 1993, 20, 211-214.

- Altered topoisomerase I activity and RAG1 gene expression in a human cell line resistant to doxorubicin.

J.F. RIOU, L. GRONDARD, O. PETITGENET, M. ABITBOL and F. LAVELLE

Biochem. Pharmacol., 1993, 46, 851-861.

- Molecular and cellular interactions between intoplicine, DNA and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy.

H. MORJANI, J.F. RIOU, I. NABIEV, F. LAVELLE and M. MANFAIT

Cancer Research, 1993, 53, 4784-4790.

- Dual topo I and II inhibition by RP 60475, a new antitumor agent in early clinical trial.

B. PODDEVIN, J.F. RIOU, F. LAVELLE and Y. POMMIER

Molecular Pharmacology, 1993, 44, 767-774.

- Docetaxel (RP 56976, NSC 628503) : current status of development.  
S. ANDRE, M.C. BISSERY, J.F. RIOU, M. BAYSSAS, N. LE BAIL and F. LAVELLE

Cellular Pharmacology, 1993, 1 (suppl. 1), 567-571.

- Experimental antitumor activity of intoplicine (RP 60475, NSC 645008), a new DNA topoisomerase inhibitor.  
M.C. BISSERY, C.H. NGUYEN, E. BISAGNI, P. VRIGNAUD and F. LAVELLE

Investigational New Drugs, 1993, 11, 263-277.

- Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.  
J.F. RIOU, P. FOSSE, C.H. NGUYEN, A. KRAGH-LARSEN, M.C. BISSERY, L. GRONDARD, J.M. SAUCIER, E. BISAGNI and F. LAVELLE

Cancer Res., 1993, 53, 5987-5993.

- Intercalating and non-intercalating antitumor drugs : structure-function correlations as probed by surface-enhanced Raman spectroscopy.  
M. MANFAIT, I. CHOURPA, K. SOKOLOV, H. MORJANI, J.F. RIOU, F. LAVELLE and I. NABIEV

In XIII International Conference on the Spectroscopy of Biological Molecules (THEOPHANIDES T., *et al.* eds), Kluwer Academic Publishers, Dordrecht, pp. 59-64 (1993).

- Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of Taxotere (docetaxel).  
I. OJIMA, O. DUCLOS, M. ZUCCO, M.C. BISSERY, C. COMBEAU, P. VRIGNAUD, J.F. RIOU and F. LAVELLE

J. Med. Chem., 1994, 37, 2602-2608.

- Molecular interactions of DNA topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes. Binding models and biological effects for intoplicine derivatives.  
I. NABIEV, I. CHOURPA, J.F. RIOU, F. LAVELLE and M. MANFAIT

Biochemistry, 1994, 33, 9013-9023.